An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs

Mojca Skoberne,a Rhonda Cardin,b Alexander Lee,a Ana Kazimirova,a Veronica Zielinski,a Danielle Garvie,a Amy Lundberg,a Shane Larson,a Fernando J. Bravo,b David I. Bernstein,b Jessica B. Flechtner,a Deborah Longa

Genocea Biosciences, Inc., Cambridge, Massachusetts, USAA; Cincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, Cincinnati, Ohio, USA

Immunotherapeutic herpes simplex virus 2 (HSV-2) vaccine efficacy depends upon the promotion of antigen-specific immune responses that inhibit reactivation or reactivated virus, thus controlling both recurrent lesions and viral shedding. In the present study, a candidate subunit vaccine, GEN-003/MM-2, was evaluated for its ability to induce a broad-spectrum immune response in mice and therapeutic efficacy in HSV-2-infected guinea pigs. GEN-003 is comprised of HSV-2 glycoprotein D2 (gD2ΔTMR340-363) and a truncated form of infected cell polypeptide 4 (ICP4383-766), formulated with Matrix M-2 (MM-2) adjuvant (GEN-003/MM-2). In addition to eliciting humoral immune responses, CD4+ and CD8+ T cells characterized by the secretion of multiple cytokines and cytolytic antigen-specific T cell responses that were able to be recalled at least 44 days after the last immunization were induced in immunized mice. Furthermore, vaccination with either GEN-003 or GEN-003/MM-2 led to significant reductions in both the prevalence and severity of lesions in HSV-2-infected guinea pigs compared to those of phosphate-buffered saline (PBS) control-vaccinated animals. While vaccination with MM-2 adjuvant alone decreased recurrent disease symptoms compared to the PBS control group, the difference was not statistically significant. Importantly, the frequency of recurrent viral shedding was considerably reduced in GEN-003/MM-2-vaccinated animals but not in GEN-003- or MM-2-vaccinated animals. These findings suggest a possible role for immunotherapeutic GEN-003/MM-2 vaccination as a viable alternative to chronic antiviral drugs in the treatment and control of genital herpes disease.

Herpes simplex virus 2 (HSV-2) is one of the most prevalent sexually transmitted diseases, having infected more than 500 million people worldwide, with an estimated 23 million new infections occurring annually (1). HSV-2 infects epithelial cells of the genital mucosa during primary infection, followed by the establishment of latency in neuronal dorsal root ganglia via retrograde transport along nerve axons. Throughout latency, virus can reactivate, causing genital lesions and/or asymptomatic shedding of virus. Although suppressive antiviral therapy has shown promise in reducing both symptomatic recurrent lesions and overall viral shedding, subclinical HSV reactivation persists, likely contributing significantly to the observed continued transmission (2). The development of an efficacious immunotherapeutic vaccine targeting HSV-2 likely represents the best strategy for preventing both lesion outbreaks and the continued spread of virus.

Despite considerable effort, all vaccine candidates to date have failed to meet their defined endpoints in clinical trials. The majority of clinical trials to date have focused on prophylactic subunit vaccines, largely using the HSV-2 surface glycoproteins as immunogens. The viral envelope glycoproteins gD and gB are the dominant targets for neutralizing antibody production (3, 4), making them logical candidates for vaccine development. A prophylactic vaccine comprised of truncated gD2 and gB2 combined with MF59 adjuvant, however, failed to demonstrate efficacy in placebo-controlled trials (5). In a recent study, a gD2 subunit vaccine, formulated with an alum/monophospholipid A adjuvant, was found to be ineffectual in men and HSV-1-seropositive women; however, it initially demonstrated significantly reduced HSV-2 disease in a subgroup analysis of HSV-1- and HSV-2-seronegative women (6). Unfortunately, a subsequent clinical trial focused on this subgroup failed to reproduce this protection against either HSV-2 disease or infection (7).

Considerable and varied efforts have been made to develop vaccines aimed at preventing HSV-2 transmission and recurrent disease. Preclinical studies of vaccines utilizing DNA, recombinant HSV glycoproteins, live attenuated viruses, and combinations have demonstrated some success (8–13). A phase 2 clinical trial was conducted to assess the efficacy of a vaccine comprised of a gH-deleted disabled infectious single-cycle (DISC) mutant in symptomatic HSV-2-infected individuals, but neither viral shedding nor recurrence rates were reduced (14). When vaccines similar to those used in prophylactic trials were evaluated, treatment with a gD2/gB2 subunit vaccine led to a slight reduction in the duration and severity of recurrent lesions, suggesting that an immunotherapeutic vaccine might be achievable (15). The results of these clinical trials demonstrate the need to improve protection, which may require changes in dosing schemes, adjuvant optimization, and the addition of other antigenic targets capable of inducing antigen-specific CD4+ and CD8+ T cell populations.

T cells have been shown to play a major role in anti-HSV immunity in both animal models and humans. While CD8+ T cells have been shown to be important for the clearance of HSV infection, CD4+ T cells are necessary to provide helper functions that...
sustain anti-HSV CD8+ T cell immunity and promote antibody class switching. Reactivation of HSV-1 in infected mouse trigeminal ganglia is blocked by CD8+ T cells secreting gamma interferon (IFN-γ) (16–18), and CD4+ T cells secreting IFN-γ are critical for immune protection against lethal genital HSV-2 infection in mice (19, 20). In humans, HSV-specific CD8+ T cells with IFN-γ effector functions have been recovered from trigeminal ganglia (21). In addition, reduced numbers of CD4+ T cells among patients with AIDS have been associated with a significant increase in HSV-2 shedding (22). CD4+ and CD8+ T cells have been shown to recognize epitopes in HSV glycoproteins, tegument proteins, and intermediate-early (IE) proteins (18, 23, 24).

Given the relative importance of T cell immune responses for controlling viral reactivation and HSV disease, our approach for development of an immunotherapeutic HSV-2 vaccine was to combine gD2, a primary target antigen for antibody and CD4+ T cell responses to HSV disease, with our approach for viral shedding, compared to those of phosphate-buffered saline (PBS). All animals were vaccinated subcutaneously (s.c.) in the scruff of the neck. For acute immunogenicity studies, animals were immunized twice, three weeks apart, with 10 to 24 μg of each recombinant protein, with 10 to 24 μg of the immune-stimulating complex adjuvant Matrix M-2 (MM-2; Isconova, Uppsala, Sweden) formulated in phosphate-buffered saline (PBS). All animals were vaccinated subcutaneously (s.c.) in the scruff of the neck. For acute immunogenicity studies, animals were immunized twice, three weeks apart, and immunogenicity analysis was performed seven days after the second immunization. For in vivo cytotoxicity studies, mice were immunized three times, three weeks apart, and in the recall studies, the mice were rested until day 86, when responses were recalled with a fourth immunization. Control animals for the memory studies were immunized only on day 86 (control for recall immunization), and immunogenicity and cytotoxicity were evaluated for all groups 5 days later (day 91). All animal care and procedures were conducted with the approval of the Institutional Animal Care and Use Committee guidelines of Vivisource Laboratories, Cambridge, MA.

(i) Mouse immunogenicity. Female C57Bl/6 mice, 6 to 8 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA). Vaccine formulations in all experiments involving mice were comprised of 1 to 2 μg of each recombinant protein, with 10 to 24 μg of the immune-stimulating complex adjuvant Matrix M-2 (MM-2; Isconova, Uppsala, Sweden) formulated in phosphate-buffered saline (PBS). All animals were vaccinated subcutaneously (s.c.) in the scruff of the neck. For acute immunogenicity studies, animals were immunized twice, three weeks apart, and immunogenicity analysis was performed seven days after the second immunization. For in vivo cytotoxicity studies, mice were immunized three times, three weeks apart, and in the recall studies, the mice were rested until day 86, when responses were recalled with a fourth immunization. Control animals for the memory studies were immunized only on day 86 (control for recall immunization), and immunogenicity and cytotoxicity were evaluated for all groups 5 days later (day 91). All animal care and procedures were conducted with the approval of the Institutional Animal Care and Use Committee guidelines of Vivisource Laboratories, Cambridge, MA.

(ii) Guinea pig therapy. Female Hartley guinea pigs, weighing approximately 250 to 300 g, were purchased from Charles River Breeding Laboratories (Wilmington, MA). Vaccine formulations were comprised of 15 μg of each recombinant protein in the presence or absence of 50 μg MM-2 adjuvant in PBS or PBS alone. All animals were vaccinated subcutaneously in the scruff of the neck. The therapeutic model is described below. All animal care and procedures were conducted with the approval of the Institutional Animal Care and Use Committee guidelines of Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Cell-mediated immune response. (i) CBA and IFN-γ enzyme-linked immunosorbent spot (ELISPOT) assays. Antigen-specific IFN-γ-positive CD4+ and CD8+ T cells were detected and quantitated as previously described (30). Briefly, splenic CD4+ and CD8+ T cells, derived from immunized mice, were enriched by magnetic bead isolation, reseeded at a final concentration of 4 × 10^6/ml in RPMI 1640 medium (Mediatech, Manassas, VA) supplemented with 10% (vol/vol) heat-inactivated FBS (HyClone, Logan, UT), 100 U penicillin, and 10 μg streptomycin per ml, 2 mM l-glutamine, 1 mM sodium pyruvate (Mediatech), and 55 μM β-mercaptoethanol (Invitrogen Life Technologies), and plated at a density of 2 × 10^5 cells per well on polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA) precoated with anti-mouse IFN-γ capture antibody (Mabtech, Nacka Strand, Sweden). Naïve mouse
splenocytes were used as antigen-presenting cells (APC) by being pulsed for 2 h at 37°C with 1 µg/ml of OLPs or 50 ng/ml of phorbol myristate acetate (PMA) plus 1 µm of ionomycin calcium salt (EDM Chemicals, San Diego, CA). A total of 1 × 10^6 pulsed APCs per well were added to the plated T cells and incubated for 18 h at 37°C. Supernatants were harvested and subjected to cytometric bead array (CBA) analysis to detect levels of tumor necrosis factor alpha (TNF-α), interleukin 2 (IL-2), IL-10, IL-4, and IL-6 production by following the manufacturer’s instructions (BD Biosciences, San Jose, CA).

After supernatant remaining, remaining cells were removed and PVDF membranes were washed extensively. Captured IFN-γ was detected by incubation with a biotinylated anti-IFN-γ antibody (Mabtech), and spots were visualized using the Vector Biolabs Vectastain ABC kit (Phila-

Philadelphia, PA) and amino-9-ethylcarbazole (AEC) substrate kit (BD Biosciences).

Spot-forming units (SFU) were quantified using an ELISPOT reader system (ZellNet Consulting, Fort Lee, NJ).

(ii) In vivo cytotoxicity. An in vivo killing assay was performed as described elsewhere (31) with minor modifications. Splenocytes from native C57BL/6 mice were pulsed with the indicated OLPs or left unpulsed and then labeled with 5 (and 6)-carboxyfluorescein (FAC) diacetate succinimimidyl ester (CFSE; Invitrogen Life Technologies). Unpulsed cells were labeled with 250 nM CFSE, and the two OLP-pulsed splenocyte populations were separately labeled with 1 µM and 4 µM CFSE. After CFSE staining was quenched with ice-cold Optimizer Cell Therapy Systems medium (Invitrogen Life Technologies), the three differentially CFSE-labeled splenocyte populations were combined in equal ratios, and an aliquote was analyzed by flow cytometry to ensure proper CFSE labeling. A total of 1 × 10^5 labeled cells were intravenously (i.v.) transferred into groups of mice (n = 5 to 6) that had been previously immunized with GEN-003/MM-2 or negative controls. Sixteen hours later, recipient mice were euthanized and their splenocytes were examined for the presence of GEN-003/MM-2 or negative controls. Sixteen hours later, recipient mice were fed.

Humoral response. (i) Antigen-specific antibody titers. Antibody titers were determined by standard antigen-specific enzyme-linked immuno-


sorbert assays (ELISA) as previously described (30). Briefly, ELISA plates were coated overnight at 4°C with either 0.5 µg/ml gD2 ΔTM or 5.0 µg/ml ICP4383-766 protein diluted in coating buffer. Serially diluted mouse serum or guinea pig plasma samples were added to washed and blocked antigen-coated plates, followed by incubation for 2 h at room temperature. Bound gD2 ΔTM- or ICP4383-766-specific antibodies were detected with either alkaline phosphate (AP)-conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis, MO), IgG1 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), or IgG2a (Southern Biotech, Birmingham, AL) or AP-conjugated anti-guinea pig IgG (Sigma-Aldrich) and SigmaFAST p-nitrophenyl phosphate (pNPP; Sigma; Aldrich) sub-

strate. The resultant optical density at 405 nm (OD405) and the regression line representing the best fit for the data were calculated via GraphPad Prism and Excel software. The endpoint titer was defined as the reciprocal of the serum dilution resulting in an OD405 equal to twice the background.

(ii) Neutralization analysis. Antibody-mediated neutralization of vi-

ral infectivity was determined via a β-galactosidase (β-Gal) colorimetric assay. Briefly, in 96-well microtiter plates, plasma or serum samples were serially diluted 3-fold in DMEM supplemented with 2% (vol/vol) heat-inactivated FBS in a 96-well microtiter plate. Approximately 300 PFU of HSV-2 (strain 333)Gal were added to each well and incubated for 60 min at 37°C. Two-hundred-microliter aliquots were plated in duplicate on Vero cells seeded in 96-well tissue culture plates and incubated for 18 h at 37°C. Cells were then lysed with 0.2% Triton X-100, and the plates were incubated for 30 min at 37°C in chloroform red-β-D-galactopyranoside (CPRG; Roche Applied Sciences, Indianapolis, IN) substrate. The resul-

tant absorbance was measured at 590 nm, and neutralizing antibody titer was defined as the reciprocal of the plasma or serum dilution that produced a 50% reduction in the OD590 of the virus control.

Guinea pig genital herpes therapeutic model. Guinea pigs were inf-
ected intravaginally with HSV-2 and randomized into treatment groups based on acute lesion scores as previously described (32). On day 2 postinfection, vaginal swabs were assayed for infection by quantitative real-time PCR. Animals with no detectable virus were removed from the study. On days 14, 21, and 36 postinfection, animals were immunized s.c. either with (i) PBS, (ii) GEN-003 (gD2 ΔTM and ICP4383-766), or (iii) GEN-003/ MM-2 (gD2 ΔTM and ICP4383-766 with MM-2 adjuvant). Animals were scored daily for 48 days (days 15 to 63 postinfection) for the severity of recurrent lesions using a previously described severity scale (33). In this scale, lesions range from 0, representing no disease, to 4, representing severe vesicululcerative skin disease of the perineum.

Viral shedding. Vaginal swabs were collected from HSV-2-infected guinea pigs as previously described (32). DNA was extracted from 200 µl of vaginal swab samples using the QIAamp 96 DNA Swab BioRobot kit (Qiagen, Germantown, MD). Each plate included no template wells (neg-

ative controls) and four 10-fold dilutions of HSV-2 strain 333 (positive controls). The number of HSV-2 DNA copies was quantified by real-time PCR using the TaqMan assay and the StepOnePlus real-time PCR system (Invitrogen Life Technologies) with primers and probes specific for HSV-2 glycoprotein G2 (gG2) designed by the Primer Express Software (Invitrogen Life Technologies). The gG2 primer and probe sequences were as follows: forward, 5'-CCGGAGACCCTTGGACACGACATCGTAC-3'; reverse, 5'-GACAATTTTCACTCCCTACAACGAACAT-3'; and probe, 5'-FAM)ACCACGCAGCTCGGC(GG(6-carboxytetramethylrhodamine [ TAMRA])-3'. Each 20-µl reaction was performed in duplicate and contained 5 µl of DNA, 1× TaqMan Universal Master Mix (Invitrogen Life Technologies), 0.45 µM (each) forward and reverse primers, and 0.10 µM probe. A standard curve, based on a known amount of genomic HSV-2 DNA (Ad-


anced Biotechnologies Inc., Columbia, MD), was used to determine copy number. The limit of detection was determined to be one copy per 20-µl reaction, with excellent linearity (R ≈ 0.98) over 5 logs of HSV-2 genomic DNA content.

Statistical analysis. Student’s t tests were performed using two-tailed analysis with equal variance. Recurrent lesion scores and viral shedding were analyzed by two-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparisons using Prism 5.04 (GraphPad, San Di-

go, CA). A P value of <0.05 was considered significant.

RESULTS

Generation of purified recombinant protein antigens. Recombi-

nant proteins were expressed by baculovirus-infected insect cells. As expected, gD2 ΔTM was secreted into the culture medium and ICP4383-766, was present in infected cell lysate (data not shown). Nickel and ion-exchange chromatography were used to purify the proteins, and SDS-PAGE analysis demonstrated that recombinant ICP4383-766 and gD2 ΔTM proteins migrated with the expected apparent molecular masses of ~52 kDa and ~48 kDa, respectively (Fig. 1A). The purity of both recombinant proteins was calculated to be >95% based on densitometry analysis (data not shown). The respective identities of ICP4383-766 and gD2 ΔTM were confirmed by Western blotting (Fig. 1B and C).

Based on the Western blot analysis, the protein band observed at approximately 130 kDa is predicted to be an ICP4383-766 dimer formed through hydrophobic interactions.

GEN-003/MM-2 vaccine induces virus- and antigen-specific antibody responses in mice. Sera collected from mice immunized with GEN-003/MM-2 vaccine 7 and 55 days after the third immu-


nization and 5 days after a fourth immunization were analyzed for anti-gD2 ΔTM or -ICP4383-766 IgG1 and IgG2c antibodies by anti-


gen-specific ELISA. As shown in Fig. 2A, immunization with
GEN-003/MM-2 elicited robust anti-gD2/H9004 TMR and anti-ICP4383-766 IgG1 and IgG2c titers, indicating a balanced Th1/Th2 response. We observed a slightly higher, but not significantly so ($P > 0.05$), antibody response to gD2/H9004 TMR than to ICP4383-766 after three or four immunizations with GEN-003/MM-2. No significant boost in IgG1 or IgG2c antibody titers was observed following the fourth immunization compared to the titers measured after three immunizations for either ICP4383-766 or gD2ΔTMR antigens. The IgG1 and IgG2c antibody responses were sustained for at least 55 days after the third immunization, suggesting that a durable and balanced Th1/Th2 antibody response is elicited by vaccination with GEN-003/MM-2.

There is considerable evidence in animal models that an efficacious prophylactic HSV-2 vaccine will most likely include a robust neutralizing antibody response (19, 34, 35); therefore, we theorized that neutralizing antibodies would also be essential for limiting secondary or cell-to-cell spread of virus replication after reactivation from latency. To determine the effect of GEN-003/MM-2 vaccination on neutralizing antibody production and durability, neutralizing antibody titers were measured in sera from GEN-003/MM-2-immunized mice. We developed a microneutralization assay based on the colorimetric quantitation of β-ga-

---

**FIG 1** SDS-PAGE analysis of purified recombinant proteins. After purification from baculovirus-infected cell cultures, antigens were electrophoresed through a 4 to 20% Tris-glycine polyacrylamide gel under reducing conditions and visualized by Coomassie blue staining (A) or Western blot analysis with either an ICP4-specific polyclonal antiserum (B) or a gD-specific monoclonal antibody (C). Prestained molecular mass markers were run on the same gel. Lane 1, ICP4383-766 (300 ng); lane 2, gD2ΔTMR (300 ng); lane 3, ICP4383-766 mixed with gD2ΔTMR (300 ng each).

**FIG 2** Antibody response to GEN-003/MM-2 vaccine formulation. C57BL/6 mice ($n = 15$) were immunized s.c. three times at three-week intervals with the GEN-003/MM-2 vaccine formulation (2 μg of each antigen plus 20 μg MM-2). Five mice per group received a fourth immunization 44 days after the third immunization. Serum samples were taken from five mice by cardiac puncture seven and 55 days after the third immunization and four days after the fourth immunization. (A) Serum samples were serially diluted 5-fold, and antibody titers to ICP4383-766 and gD2ΔTMR protein were measured by endpoint ELISA. IgG1 and IgG2c endpoint titers are shown as the mean ± the standard error of the mean (SEM) per group. (B) Neutralizing antibody titers to virus were determined using a colorimetric assay as described in Materials and Methods. Titers are shown as the mean ± SEM titer that resulted in 50% neutralizing activity per GEN-003/MM-2 vaccine-immunized group. No ELISA or neutralizing antibody titers were detected in serum from naïve mice or MM-2 adjuvant-immunized mice. $P$ values were calculated by Student’s $t$ test. Data are representative of two experiments. NS, not significant.
lactosidase expression from HSV-2/Gal infection (27). Antibody titers inducing HSV-2 neutralization were determined by linear regression analysis of the optical density values. Previous studies showed a good correlation between the microneutralization assay and a direct assessment of 50% plaque reduction, with less than 25% variation in antibody titers between the two methods. As shown in Fig. 2B, a strong HSV-2 neutralizing antibody titer was elicited in mice receiving three or four immunizations of GEN-003/MM-2. The mean neutralizing antibody titer decreased from 589 to 391 between 7 and 55 days after the third immunization (not significant; \( P = 0.34 \)), suggesting that a durable neutralizing antibody response is elicited by the GEN-003/MM-2 vaccine.

In summary, robust antibody responses are generated against the protein antigens contained in the GEN-003/MM-2 vaccine. The responses were high titer, neutralizing, and a balanced Th1 and Th2 phenotype. Both the antigen-specific IgG1 and IgG2c antibody titers and the HSV-2 neutralization activity persisted for at least 55 days after the third immunization.

The GEN-003/MM-2 vaccine elicits antigen-specific cellular immune responses in mice. ELISPOT analysis was performed to measure IFN-\( \gamma \) production by CD4\(^+\) and CD8\(^+\) T cells in mice immunized with the GEN-003/MM-2 vaccine formulation. Mice were immunized s.c. twice, three weeks apart, with a 100-\( \mu \)g formulation containing 5 \( \mu \)g each of gD2\( \Delta \)TMR and ICP4383-766 plus 24 \( \mu \)g of MM-2 diluted in PBS or appropriate controls. Splenic T cells were enriched from immunized mice 1 week after the second immunization. CD8\(^+\) T cells isolated from splenocytes of mice immunized with the GEN-003/MM-2 vaccine or another baculovirus-derived recombinant HSV-2 protein, ICP5/MM-2, produced only background levels of IFN-\( \gamma \) in response to irrelevant antigens (i.e., ICP5, 10 to 37 SFU per 200,000 T cells) compared with vaccine antigen-specific IFN-\( \gamma \) production (150 to 444 SFU per 200,000 T cells). This demonstrates that observed IFN-\( \gamma \) levels are not resulting from nonspecific activation by contaminating baculovirus or cellular proteins (Fig. 3A). Subsequent T cell stimulations were performed with antigen-specific overlapping peptide (OLP) pools. Robust, antigen-specific IFN-\( \gamma \) responses to both gD2\( \Delta \)TMR and ICP4383-766 antigens were measured in both CD4\(^+\) and CD8\(^+\) T cell subsets, and there were no detectable responses to the negative-control peptides (Fig. 3B).
this immunization dose, the response to the ICP4<sub>383-766</sub> antigen was significantly higher than the response to gD2ΔTMR for CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets (P < 0.01 and 0.04, respectively). The magnitude of response to both antigens was quite high, however, with the frequency of responding cells ranging from 0.1 to 0.5% of the overall T cell population. There were no measurable T cell responses in mice immunized with the antigens alone in the absence of MM-2 (data not shown).

Previous research has indicated that effector T cell responses, characterized by the secretion of the Th1-type cytokines IFN-γ, IL-2, and TNF-α, are required for mounting an effective immune response to HSV infection (19). To determine the antigen-specific cytokine profile induced after GEN-003/MM-2 immunization, cytometric bead array (CBA) analysis was performed using supernatants harvested from the IFN-γ ELISPOT assay to determine the relative levels of Th1- and Th2-type cytokines present in the supernatants. The responses to the negative-control peptides ranged from undetectable for TNF-α and IL-2 to below 40 pg/ml for IL-6. Significant antigen-specific TNF-α, IL-2, and IL-6 cytokine responses were measured for CD4<sup>+</sup> and CD8<sup>+</sup> T cells derived from the GEN-003/MM-2-immunized mice (Fig. 3C), whereas IL-4 responses were low (20 to 40 pg/ml) and IL-10 was undetectable (<5 pg/ml; data not shown). The pattern of these cytokines mirrored that seen in the IFN-γ ELISPOT assay, in which the responses to the ICP4<sub>383-766</sub> antigen were greater than those to the gD2ΔTMR antigen. These data suggest that multiple cytokines associated with polyfunctionality are produced by antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells after GEN-003/MM-2 immunization.

Resolution of herpetic lesions has been correlated with the presence of HSV-specific cytotoxic T lymphocytes (CTLs), indicating their critical role in limiting recurrent disease (24, 36). Thus, the effector function of antigen-specific T cells was evaluated in GEN-003/MM-2-immunized mice by an in vivo cytotoxicity assay. C57BL/6 mice were immunized s.c. three times, 21 days apart, with 2 µg of each antigen plus 10 µg or 20 µg MM-2. Six days after the third immunization, a mixed population of CFSE-labeled and OLP-pulsed splenocytes derived from naïve mice was adoptively transferred by i.v. injection. Sixteen hours later, spleens were harvested and the proportion of CFSE-labeled cells was determined by flow cytometry. As shown in Fig. 4C, there was more than 50% specific lysis of ICP4<sub>383-766</sub> OLP-pulsed target cells and approximately 30% specific lysis of gD2ΔTMR OLP-pulsed target cells relative to the unpulsed CFSE-labeled population (Fig. 4B, peak a) adoptively transferred into the same immunized mice. These data indicate that the T cells elicited by immunization with the GEN-003/MM-2 vaccine have functional cytolytic activity in addition to secreting effector cytokines.

To determine if this antigen-specific cytolytic activity persists over time, CFSE-labeled and OLP-pulsed target splenocytes were adoptively transferred into immunized mice 91 days after their primary immunization. Briefly, as described above, one group of mice received three immunizations, 21 days apart, with 2 µg of each antigen plus 20 µg of MM-2 while the control group of mice did not receive the vaccine. The mice were then rested to allow development of memory responses. On day 86 (44 days after the third dose), any existing antigen-specific cells were recalled by in vivo stimulation of vaccinated and control mice with GEN-003/MM-2 followed by in vivo cytolytic evaluation of antigen-specific T cells 5 days later, as described in Materials and Methods. The recall was performed to activate and expand the persisting T cells so that antigen-specific cytolytic activity would be above the assay’s sensitivity level and therefore measurable. GEN-003/MM-2-immunized mice demonstrated antigen-specific lysis of OLP-pulsed target cells. The time between recall in vivo stimulation and in vivo cytolytic activity measurement was short (5 days); however, theoretically, it may be sufficient to allow priming of antigen-specific T cells in the control group of mice. Therefore, the cytolytic activities of vaccinated and control mice were compared, and a statistically significant increase in cytolyis by T cells of vaccinated animals compared to that by T cells of the control animals was confirmed (Fig. 4).

Taken together, these data indicate that the GEN-003/MM-2 vaccine formulation elicits both ICP4<sub>383-766</sub> and gD2ΔTMR-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses that secrete multiple cytokines in response to antigen stimulation. Moreover, the T cell responses are functionally cytolytic in vivo and can be recalled at least 44 days after the third immunization.

Effect of therapeutic immunization on recurrent HSV-2 disease in guinea pigs. HSV-2 infection in guinea pigs induces recurrent lesions and viral shedding, similar to the human course of infection and disease symptoms (37). To examine the potential therapeutic effect of vaccination with either of the HSV-2 proteins alone (plus MM-2), GEN-03, or the GEN-003/MM-2 vaccine, guinea pigs were intravaginally infected with 5 × 10<sup>6</sup> PFU of HSV-2 strain MS and subsequently immunized s.c. three times at 14, 21, and 36 days postinfection. Anti-ICP4<sub>383-766</sub> and -gD2ΔTMR IgG titers were measured by ELISA on day 42 postinfection, six days after the third immunization. Infected, PBS- or MM-2-immunized animals developed detectable antibody to gD2ΔTMR but not ICP4<sub>383-766</sub> (Fig. 5A and C). A statistically significant increase in antibody titers to ICP4<sub>383-766</sub> protein was observed in the GEN-003/MM-2-vaccine-immunized group compared to that in the groups receiving GEN-003 or PBS. Relative to the infected, PBS-immunized group, HSV-2-infected animals therapeutically immunized with GEN-003 or the GEN-003/MM-2 vaccine had a 7- or 14-fold increase in gD2ΔTMR antibody titer, respectively (Fig. 5A). Immunization with GEN-003/MM-2 boosted neutralizing antibody titers as well, with approximately 3-fold higher levels than in PBS-immunized, HSV-2-infected animals (Fig. 5B) (P = 0.001), presumably due to the increase in gD2 antibody.

The effect of vaccination on recurrent disease is shown in Fig. 6. HSV-2-infected guinea pigs were examined daily for the severity of lesions as well as the appearance of new recurrent lesions from day 15 through day 63 postinfection. As shown in Fig. 6A and Table 1, therapeutic immunization with ICP4<sub>383-766</sub>, or gD2 plus MM-2 significantly reduced the mean cumulative recurrent lesion scores by 49% or 53%, respectively, compared to the PBS control group (P < 0.05). In comparison, immunization of HSV-2-infected guinea pigs with ICP5 plus MM-2 was less effective, with only a 26% reduction in the severity of the clinical lesion score (P > 0.05) relative to the PBS control group. A slight decrease in severity scores was also noted with MM-2 alone (17%), but only after the third immunization, and it was not statistically significant compared to the PBS control group. Vaccination with either gD2 or ICP4<sub>383-766</sub> significantly decreased the number of recurrent lesion days compared to that in the PBS-vaccinated group (Fig. 6B) (P = 0.035 and P = 0.033, respectively). MM-2 alone or ICP5/MM-2 vaccination had a small effect that was not
significant relative to the PBS-vaccinated control group. In a second experiment, shown in Fig. 6C and Table 1, the mean recurrent lesion scores for the GEN-003- and GEN-003/MM-2-vaccinated groups were reduced compared to that of the PBS control group (4.2 ± 2.9 and 3.9 ± 3.0 versus 8.6 ± 3.8, respectively), representing a 51% reduction for GEN-003 and a 55% reduction for GEN-003/MM-2 (P values of <0.05 for both versus the PBS control). The frequency of recurrent lesion days was also significantly reduced by approximately 45% in the GEN-003- and GEN-003/MM-2-immunized groups compared to that in the PBS control group (Fig. 6D) (P = 0.01). There was no significant difference between the GEN-003 and GEN-003/MM-2 groups. In another experiment, we compared the effectiveness of GEN-003/MM-2 vaccination to that of MM-2 adjuvant alone on recurrent lesion symptoms. Although cumulative lesion scores were not significantly reduced in animals receiving GEN-003/MM-2 vaccine rel-
To determine the effect of therapeutic vaccination on viral shedding by HSV-2-infected guinea pigs, vaginal swabs were collected and evaluated for viral DNA by real-time PCR (Table 1). In the first experiment, 12 vaginal swab samples per guinea pig were collected after the second immunization, from days 22 to 63 postinfection, and assayed for the presence of HSV-2 Us4 DNA by real-time PCR. Only the ICP4383-766-vaccinated group had a significantly reduced frequency for recurrent virus shedding compared to that of the PBS control group (7.7% versus 26.9%; P < 0.05) (Table 1). Immunization with ICP5 or gD2 plus MM-2 did not significantly affect the frequency of recurrent viral shedding relative to that of the control (22.2% and 13.6%, respectively). In the second experiment, 22 vaginal swab samples per animal were collected, from days 16 to 63 postinfection, and assayed for the presence of HSV-2 Us4 DNA. In the GEN-003/MM-2 vaccine-immunized group, 12.8% of the 242 total swabs assayed were positive for HSV-2 DNA, compared to 14.0% and 15.1% positive for the GEN-003- and PBS-immunized groups, respectively (not significant) (Table 1). No significant difference in the magnitude of viral shedding was measured for either the GEN-003- or GEN-003/MM-2-immunized group (data not shown). When viral shedding was measured after the second immunization (days 21 to 63), 8.6% of samples obtained from the GEN-003 or GEN-003/MM-2 vaccine-immunized group were positive for HSV-2 DNA, compared to 10.0% of samples in the PBS-immunized group. Importantly, after the third vaccination (days 36 to 63), viral shedding was completely undetectable in GEN-003/MM-2-immunized animals while 2.6% and 4.4% of samples in the GEN-003- and PBS-immunized groups, respectively, contained detectable HSV-2 DNA (P value of <0.05 compared to the PBS control). Taken together with the analysis of the severity of recurrent lesions, these data suggest that ICP4383-766 and gD2 ΔTMR each contribute to the efficacy of the GEN-003/MM-2 vaccine and that the addition of MM-2 adjuvant to the GEN-003 vaccine antigens will create a more effective immunotherapeutic vaccine than just the antigens alone.

**DISCUSSION**

This study represents the first in vivo demonstration of the immunogenicity and therapeutic efficacy of a candidate subunit herpes

**FIG 5** Antibody responses of HSV-2-infected guinea pigs vaccinated with GEN-003 or GEN-003/MM-2 vaccine. Guinea pigs were infected intravaginally with 5 x 10⁶ PFU of HSV-2 strain MS, allowed to recover from primary disease, and then vaccinated s.c. three times on days 14, 21, and 36 postinfection with PBS, 15 µg of each antigen only (GEN-003), or 15 µg of each antigen plus 50 µg MM-2 adjuvant (GEN-003/MM-2). (A) Antibody titers in plasma samples (n = 4) to ICP4383-766 or gD2 ΔTMR were measured by endpoint ELISA at day 42 postinfection (six days after the third immunization). Data are shown as the mean ELISA endpoint titer of each group ± SEM. (B) Neutralizing antibody titers were determined by a colorimetric assay as described in Materials and Methods. The titer was defined as the reciprocal of the serum dilution required to decrease the OD₅₉₀ obtained using the virus control by 50%. Data are shown as the mean neutralizing antibody titer of each group ± SEM. P values compare the GEN-003-immunized group to the GEN-003/MM-2-immunized group or to the PBS control group using Student’s t test. (C) Antibody titers in plasma samples (n = 4) to ICP4383-766 or gD2 ΔTMR were measured by endpoint ELISA at day 42 postinfection (six days after the third immunization). P values compare the GEN-003/MM-2-vaccinated group to the MM-2 control group using Student’s t test.
FIG 6 Therapeutic treatment of infected guinea pigs with HSV-2 antigens or GEN-003 vaccine. Guinea pigs were infected intravaginally with $5 \times 10^5$ PFU of HSV-2 strain MS, allowed to recover from primary disease, and then vaccinated s.c. three times on days 14, 21, and 36 postinfection. (A and B) PBS ($n = 9$), 50 μg of MM-2 alone ($n = 12$), and 15 μg of each antigen alone plus 50 μg of MM-2 adjuvant ($n = 9$ to 11) (Table 1, experiment 1). (A) Cumulative mean lesion severity scores (as described in Materials and Methods) are shown for each group. (B) The number of days with a recurrent lesion is shown. Each symbol indicates an individual animal from the same group. The $P$ value compares the PBS control group to each antigen-immunized group using unpaired, two-tailed Student’s $t$ test. (C and D) Fifteen micrograms of each antigen (GEN-003) or 15 μg of each antigen plus 50 μg of MM-2 (GEN-003/MM-2) (Table 1, experiment 2). (C) Cumulative mean lesion severity scores (as described in Materials and Methods) are shown for each group: PBS ($n = 13$), GEN-003 ($n = 14$), and GEN-003/MM-2 ($n = 11$). (D) The number of days with a recurrent lesion is shown. Each symbol indicates individual animals from the same group. The $P$ value compares the PBS control group to the GEN-003 or GEN-003/MM-2 vaccine-immunized group using unpaired, two-tailed Student’s $t$ test. (E and F) Fifty micrograms of MM-2 or 15 μg of gDΔTMR plus 15 μg of ICP4383-766 with 50 μg of MM-2 (GEN-003/MM-2). (E) Cumulative mean lesion severity scores are shown for each group: MM-2 ($n = 19$) and GEN-003/MM-2 ($n = 20$). (F) The number of days with a recurrent lesion is shown. Each symbol indicates an individual animal from the same group. $P$ values compare the GEN-003/MM-2-vaccinated group to the MM-2 control group using unpaired, two-tailed Student’s $t$ test.
TABLE 1 Effect of ICP5, ICP4383-766, gD2, or GEN-003 vaccination on recurrent lesion scores and viral shedding in HSV-2-infected guinea pigs

<table>
<thead>
<tr>
<th>Expt and treatment group</th>
<th>Recurrent mean lesion score</th>
<th>Shedding frequency(%) (no. of samples from which DNA was detected/total no. of samples analyzed)</th>
<th>After 1st immunization</th>
<th>After 2nd immunization</th>
<th>After 3rd immunization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expt 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBS</td>
<td>9</td>
<td>9.0 ± 5.7</td>
<td>7.8 ± 5.0</td>
<td>26.9 (29/108)</td>
<td>5.3 ± 2.9</td>
</tr>
<tr>
<td>MM-2</td>
<td>12</td>
<td>7.5 ± 4.7</td>
<td>6.0 ± 4.0</td>
<td>16.0 (23/144)</td>
<td>3.7 ± 2.6</td>
</tr>
<tr>
<td>ICP5/MM-2</td>
<td>9</td>
<td>6.7 ± 3.9</td>
<td>5.8 ± 3.2</td>
<td>22.2 (24/108)</td>
<td>3.6 ± 2.0</td>
</tr>
<tr>
<td>ICP4383-766/MM-2</td>
<td>11</td>
<td>4.6 ± 2.5</td>
<td>4.3 ± 2.5</td>
<td>7.7 (10/130)</td>
<td>2.4 ± 1.7</td>
</tr>
<tr>
<td>gD2 (EC)/MM-2</td>
<td>11</td>
<td>4.2 ± 2.4</td>
<td>3.9 ± 2.3</td>
<td>13.0 (17/131)</td>
<td>3.0 ± 1.9</td>
</tr>
<tr>
<td>Expt 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBS</td>
<td>13</td>
<td>8.6 ± 3.8</td>
<td>6.3 ± 3.0</td>
<td>10.0 (26/260)</td>
<td>3.8 ± 2.8</td>
</tr>
<tr>
<td>GEN-003</td>
<td>14</td>
<td>4.2 ± 2.9</td>
<td>3.6 ± 2.5</td>
<td>8.6 (24/280)</td>
<td>2.5 ± 2.2</td>
</tr>
<tr>
<td>GEN-003/MM-2</td>
<td>11</td>
<td>3.9 ± 3.0</td>
<td>3.6 ± 2.6</td>
<td>8.6 (19/220)</td>
<td>2.3 ± 2.1</td>
</tr>
</tbody>
</table>

\(a\) Guinea pigs were infected by intravaginal inoculation of \(5 \times 10^5\) PFU of HSV-2 strain SM and immunized on days 14, 21, and 36 postinfection (p.i.). Experiment 1 included PBS, 50 \(\mu\)g MM-2 adjuvant, and 15 \(\mu\)g of ICP5, ICP4383-766 or Escherichia coli-derived gD2 (EC) with 50 \(\mu\)g MM-2. Experiment 2 included 15 \(\mu\)g of gD2ΔTMR and 15 \(\mu\)g ICP4383-766 (GEN-003) or 15 \(\mu\)g of each antigen with 50 \(\mu\)g MM-2 adjuvant (GEN-003/MM-2). Vaginal swab samples were collected from each animal between days 22 and 63 (experiment 1, \(n = 12\)) and days 16 and 63 (experiment 2, \(n = 22\)) and processed as described in Materials and Methods.

\(b\) Shedding frequency = (number of vaginal swab samples from which viral DNA was detected/total number of vaginal swab samples analyzed) \(\times 100\). ND, not determined.

\(c\) \(P\) value of \(<0.05\) compared to the PBS control group using a chi-square test.

\(d\) \(P\) value of \(<0.05\) compared to the PBS control group using a two-way ANOVA with Bonferroni’s multiple comparisons.
This builds on the findings by other researchers, who have shown
 cellular responses, including IFN-γ expression and induction of
cytotoxic CD4+ and CD8+ T cells by recombinant gD vaccination,
 in mouse HSV immunization models (19, 57). Limited stud-
ies to characterize the cellular responses elicited by IC P4 in mice
have been performed (58, 59). Martin et al. (59) showed that HSV-
specific T cells lysed IC P4-expressing target cells in vitro, but none
of the immunized mice generated antigen-specific cytotoxic T cell
responses. These results are inconsistent with our findings show-
 ing significant IC P4-specific cytotoxic activity elicited in vivo but
can be explained by poor expression of the IC P4 gene by the vac-
cinia vector used for immunization in the study by Martin et al.

Adjuvant selection is critical for facilitating the desired im-
mune response to protein antigens. Matrix M is a novel, saponin-
based adjuvant that has demonstrated a balanced B and T cell
immunostimulatory profile (55). In our mouse studies, immuniza-
tion with 2 μg of each recombinant HSV-2 protein and 20 μg of
MM-2 elicited strong antigen-specific IgG1 and IgG2c titers that
persisted for at least 55 days after the third immunization, indi-
cating a durable and balanced Th1/Th2 cytokine profile. In our
studies, both gD2 and IC P4 antigens activated CD4+ and CD8+
T cells to produce Th1-type cytokines, IFN-γ and IL-2, that pro-
mote CD8+ T cell proliferation and facilitate isotype switching to
IgG2a production (equivalent to the IgG2c subtype in C57BL/6
mice [60]) by antibody-secreting cells (61). Induction of IgG2a
with enhanced complement-fixing capability is one of the hall-
marks of a Th1 response profile in mice and provided superior
protection against HSV challenge (62, 63). We also observed the
induction of strong HSV-2 neutralizing antibody titers in GEN-
003/MM-2-immunized mice, which was induced by the gD2 an-
tigen (data not shown). Previous studies demonstrated a more
potent neutralizing capacity associated with the IgG2a serum frac-
tion than with the IgG1 isotype, suggesting that a greater propor-
tion of IgG1 antibody may be directed to nonneutralizing epitopes
(64). Moreover, investigators have reported that HSV infection in
humans preferentially induces the IgG1 isotype, distinguishing
HSV from many other viral infections (65, 66). These studies sup-
port the idea that induction of virus-specific neutralizing antibod-
ies that skew to a Th1-type response, with the promotion of func-
tional IgG2a antibody production, may be facilitated by an
immunotherapeutic vaccine and effectively control HSV infec-
tion.

Guinea pigs vaginally infected with HSV-2 demonstrate a
 course of acute and recurrent disease similar to that observed
in humans. The guinea pig model has not been predictive of HSV-2
vaccine efficacy in human clinical trials; however, work by Bourne
et al. showed that a gD2 vaccine with monophosphoryl lipid A
(MPL)/alum significantly decreased acute and recurrent clinical
disease symptoms but did not prevent mucosal infection in guinea
pigs (67). Similarly, in clinical trials, immunization with the gD2/
AS04 vaccine, which has a similar composition, provided HSV-
senonegative women significant protection against HSV-2 genital
disease symptoms but limited protection against infection (6).
Depending on the vaccine composition and adjuvant used, studies
from several groups reported reductions in outbreak frequency of
25% to 70% in immunized, infected guinea pigs (10, 12, 68, 69).
The results presented here are very encouraging, since vaccination
of infected guinea pigs with the GEN-003/MM-2 vaccine signifi-
cantly reduced recurrent lesion outbreaks by approximately 45%,
decreased the total lesion days per animal (Fig. 6D), and decreased
lesion severity scores by 55% (Fig. 6C) relative to the PBS-vacci-
nated control group. Furthermore, and of particular interest, after
the third immunization, no HSV-2 DNA was detected in any vagi-
nal swab sample from GEN-003/MM-2 vaccine-immunized an-
imals, suggesting that viral shedding was limited by vaccine admin-
istration. We also showed that vaccination of infected guinea pigs
with IC P4383-766 or gD2ΔTMR with MM-2 significantly decreased
recurrent lesion scores by 49% or 53%, respectively. While the
frequency with which animals shed virus was reduced after gD2/
MM-2 vaccination, the decrease was not significantly different
relative to the PBS control group, whereas in animals receiving
IC P4383-766/MM-2, the reduction in viral shedding was signifi-
cantly different compared to the PBS-vaccinated control group,
suggesting that immune responses to IC P4383-766 and gD2ΔTMR
play different roles in the control of viral reactivation. Thus, the
combination of IC P4383-766 and gD2ΔTMR may have an advantage
over gD2ΔTMR/MM-2 alone as a therapeutic vac-
cine. The decrease in the number of days with recurrent lesions,
lesional severity, and shedding may be due to enhanced immune
responses that control reactivation and subsequent viral replica-
 tion. Although reagents are not commercially available for mea-
 su ring T cell responses in guinea pigs, the unique impact on viral
shedding may be attributed to T cell responses, as results from
studies using the same antigens and adjuvant as immunogens in
mice demonstrate potent T cell activation. Antibody titers were
also measured in the guinea pig therapeutic model, from which a
couple observations can be drawn: (i) immunization of previously
infected animals with this subunit vaccine results in a significant
boost in antigen-specific antibody titer beyond that generated by
infection alone, and (ii) the virus neutralizing antibody titer is
3-fold higher in the vaccine group than in the PBS-immunized
control animals.

An effective therapeutic vaccine may help to reduce HSV-2
shedding in addition to limiting symptomatic recurrences. The
data presented in these studies show that the GEN-003/MM-2
vaccine meets the predicted requirements of an effective therapeu-
tic vaccine. Specific T cell responses to antigens comprising the
vaccine are cytolytic and durable, and high-titer Th1/Th2 bal-
anced antibody responses that are virus neutralizing are induced.
Finally, therapeutic administration of the GEN-003/MM-2 sub-
unit vaccine influences the course of genital herpes disease in
infected guinea pigs by reducing the frequency and severity of les-
ions and ameliorating viral shedding.

ACKNOWLEDGMENTS

We thank J. Earwood and J. Clark for excellent technical assistance
with the guinea pig model. We are grateful to Audrey Eisen-Vandervelde
for manuscript support and Louis Crowley and Bharat Dixit for recombinant
protein production and SDS-PAGE analysis.

REFERENCES

prevalence and incidence of herpes simplex virus type 2 infection. Bull.
Schiffer JT, Koelle DM, Corey L, Wald A. 2012. Standard-dose and
high-dose antiviral therapy for short episodes of genital HSV-2 reactiva-
3. Cohen GH, Dietzschold B, Leon MP, Long D, Gobu E, Varriochio A,
Pereira I, Eisenberg RJ. 1984. Localization and synthesis of an antigenic
determinant of herpes simplex virus glycoprotein D that stimulates the


Skoberne et al.